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Phase II Evaluation of VDC-1101 in Canine Cutaneous T-Cell
Lymphoma
M.A. Morges, J.H. Burton, C.F. Saba, D.M. Vail, K.E. Burgess, and D.H. Thamm
Background: Canine cutaneous T-cell lymphoma (CTCL) is an uncommon disease for which efficacious therapies are
lacking. The novel anticancer nucleotide prodrug VDC-1101 (formerly known as GS-9219) has shown efficacy in dogs with
multicentric lymphoma. One of the observed adverse effects with this drug was a skin change characterized by hair loss,
erythema, and pruritus, implying delivery of VDC-1101 to the skin.
Hypothesis/Objectives: The primary study objective was to identify the objective response rate (ORR) to VDC-1101 in
canine CTCL; secondary objectives included characterization of progression-free survival (PFS) and adverse events (AEs).
Animals: Twelve dogs with chemotherapy-na€ıve or relapsed, histologically and immunohistochemically confirmed
CTCL.
Methods: Dogs received VDC-1101 as a 30-minute IV infusion once every 21 days. Prednisone (1 mg/kg PO q48h) was
administered concurrently.
Results: In 11 evaluable patients, responses included 1 complete response (CR), 4 partial responses (PR), 2 stable dis-
ease (SD), and 4 progressive disease for an ORR of 45% and biologic response rate (CR/PR/SD) of 64%. The median
PFS was 37.5 days (26 to >399 days), which includes 1 durable and ongoing CR (>1 year). Gastrointestinal and hemato-
logic AEs were mild; no dogs developed grade 3 or 4 AEs. Three dogs developed dermatopathies and 1 of these dogs was
removed from the study as a result of this AE.
Conclusions and Clinical Importance: VDC-1101 has activity against canine CTCL and could provide another treatment
option in a disease process with a poor prognosis.
Key words: Cancer; Chemotherapy; Dog; Mycosis fungoides.
Canine lymphoma is one of the most common can-cers encountered in veterinary oncology, repre-
senting 20% of all malignancies in some studies,
whereas cutaneous T-cell lymphoma (CTCL), includ-
ing both epitheliotropic and nonepitheliotropic forms,
represents a less common presentation of the disease,1
with an estimated prevalence of 1% of skin tumors in
dogs.2 Cutaneous epitheliotropic T-cell (CETL) lym-
phoma represents the majority of cases with estimated
reported prevalence of 0.02–0.7%.3–5 Although most
canine multicentric lymphoma patients initially
respond to currently available chemotherapy protocols,
response rates are considerably lower in patients with
CTCL, and generally responses are brief in duration.
Cutaneous T-cell lymphoma is caused by the infiltra-
tion of malignant T cells into the skin. CTCL is a het-
erogenous group of disorders with a variety of clinical
presentations, and consists of nonepitheliotropic and
epitheliotropic forms. Clinical presentation is extremely
variable. Dogs usually are presented with a history of
chronic dermatitis, and mucocutaneous junctions or
the oral mucosa sometimes is affected. Involvement of
other organs including lymph nodes, viscera, and
peripheral blood can be observed in the late stages of
disease.1,6 The Scott classification has been used to
describe the clinical presentation of CETL and
includes exfoliative erythroderma, plaques or nodules,
ulcerative disease of the oral mucosa, and a mucocuta-
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AE adverse event
CETL cutaneous epitheliotropic T cell lymphoma
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DLT dose limiting toxicity
ECOG Eastern Cooperative Oncology Group
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ORR objective response rate
PD progressive disease
PFS progression-free survival
PMEG acyclic nucleotide phosphonate 9-(2-phosphonyl
methoxyethyl) guanine
PMEGpp PMEG disphosphate
PO per os
PR partial response
RECIST Response Evaluation Criteria in Solid Tumors
SD stable disease
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neous form,4,7 but a more recent publication found
frequent overlap of presentations with concurrent pres-
ence of all lesion types.5 In this study, the majority of
lesions were disseminated over the trunk (83.3%) or
localized to the head (63%). The footpads were
involved in 26.6% of cases. Pruritus was observed in
40% of cases and lymph node enlargement in 20%.
Several therapies have been evaluated for the treat-
ment of CTCL in dogs, including radiation therapy,8
differentiating agents (eg, retinoids, linoleic acid),9,10
and cytotoxic chemotherapeutic agents such as lomus-
tine and dacarbazine.11–13 Although objective response
rates (CR/PR) of 45–80% have been reported with
these therapies, complete responses (CR) are rare and
responses generally are brief in duration. Nearly all
dogs with CTCL eventually succumb to progressive
disease. Novel therapies for this disease clearly are nec-
essary to improve outcomes.
VDC-1101,a previously referred to as GS-9219, is a
double prodrug of the acyclic nucleotide phosphonate
9-(2-phosphonylmethoxyethyl) guanine (PMEG), which
was designed to preferentially deliver and accumulate
PMEG and its active phosphorylated metabolite,
PMEG disphosphate (PMEGpp), in lymphoid cells,
while avoiding systemic exposure of PMEG.14 Delivery
of PMEG/PMEGpp results in cytotoxicity because of
inhibition of nuclear DNA polymerases a, d, and e.15
PMEG’s clinical utility is limited by poor cellular per-
meability and gastrointestinal and renal toxicity.16–18
VDC-1101, however, is hydrolyzed intracellularly to
9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-di-
aminopurine (cPrPMEDAP), deaminated to PMEG
and then rapidly converted to PMEGpp.1 In normal
laboratory dogs, VDC-1101 selectively depletes repli-
cating lymphoid tissues at doses that spare other tis-
sues, and demonstrates substantial antineoplastic
activity in dogs with naturally occurring non-Hodgkin
lymphoma (NHL).14,19,20 One of the observed adverse
effects with this drug was a skin change characterized
by hair loss, erythema, and pruritus, implying deposi-
tion of VDC-1101 in the skin.
The purpose of this study was to identify the objec-
tive response rate (ORR) to VDC-1101 in canine
CTCL; secondary endpoints included the characteriza-
tion of progression-free survival (PFS) and adverse
events (AEs).
Materials and Methods
Enrollment in this clinical trial was according to a Simon
Minimax design, with a rule-out response probability of 5% and
a minimum useful response probability of 25%. Twelve dogs
were found to be an adequate number to detect these changes in
a pilot efficacy study. The goal of this prospective trial was to
complete initial accrual within 9 months with an additional
3 months of follow-up.
Owners of dogs with CTCL presenting as patients to the Colo-
rado State University Veterinary Medical Center (CSU-VMC),
School of Veterinary Medicine, University of Wisconsin-Madison
(UW-SVM), University of Georgia Veterinary Teaching Hospital
(UGA-VTH), and Tufts University Foster Hospital (TU-FH) for
Small Animals were offered study entry for treatment with VDC-
1101 under compliance with the Animal Care and Use Commit-
tees of all institutions. Signed informed consent was obtained
from all owners. Before entry, dogs were evaluated by physical
examination, complete blood count (CBC), serum biochemistry
profile, urinalysis, and thoracic radiography. Dogs were included
if they had a histologic and immunohistochemical diagnosis of
CTCL, adequate organ function, and a modified Eastern Com-
parative Oncology Group (ECOG) constitutional performance
score of 0 or 1 on Day 1 (Table 1). Any clinical presentation or
histologic form of CTCL was included as long as at least 1 lesion
occurred on haired skin. All histopathologic sections were con-
firmed to be CTCL by positive immunohistochemical staining for
CD3. Because histopathologic sections were submitted from sev-
eral institutions, information regarding specific histologic sub-
types was not available.
Concurrent antineoplastic treatment was not allowed, with the
exception that all dogs received prednisone (1 mg/kg PO q48h).
Previous cytotoxic chemotherapy and radiation treatment was
allowed with 3-week and 6-week washout periods, respectively.
Dogs were excluded if they were receiving homeopathic or alter-
native therapies. There was a 1-week washout period for dogs
that had received retinoids. Dogs of the West Highland White
Terrier Breed were excluded because of their genetic predisposi-
tion for pulmonary fibrosis, an uncommon but documented AE
of VDC-1011.21,22
VDC-1101 as the succinate salt was administered by a 30-min-
ute IV infusion in 0.9% NaCl for injection (2 mL/kg) at a dosage
of 1.0 mg/kg every 21 days until progressive disease (PD) or
dose-limiting toxicity, defined as any uncomplicated grade 4 neu-
tropenia or thrombocytopenia or any grade 3 or 4 nonhemato-
logic toxicity (excluding dermatopathy). This dosage and
schedule represents those that were previously defined as optimal
in pet dogs with non-Hodgkin lymphoma, based on efficacy and
tolerability.19 Patients that experienced a CR were treated for 2
cycles beyond confirmation of CR or 5 total cycles, whichever
was longer.
At each visit, owner history, physical examination, CBC,
serum biochemistry, and urinalysis were performed. Response to
treatment was assessed by modified Response Evaluation Criteria
in Solid Tumors (RECIST) criteria for patients with measurable
lesions. Briefly, up to 5 target lesions were identified per patient.
Caliper measurements of each target lesion were performed by 1
evaluator. At each response assessment, the sum of the longest
diameters was recorded and compared to baseline. Photographs
of lesions at each visit were encouraged. A CR was defined as
resolution of all measurable disease. A PR was defined as a
≥30% decrease in the sum of diameters, whereas PD was defined
as a ≥20% increase in the sum of diameters, or the development
of any new lesions. A patient was classified as stable disease (SD)
when not meeting the criteria for CR, PR, or PD. The ORR was
defined as the percentage of dogs experiencing a CR or PR at
Table 1. Modified ECOG performance status. Dogs
must have had a performance score of 0 or 1 to be
eligible.
0 Normal activity
1 Restricted activity
Decreased activity from predisease status
2 Compromised
Ambulatory only for vital activities
3 Disabled, needs to be force-fed
Is unable to confine urination and defecation to acceptable
areas
4 Dead
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any time point. Biologic response rate included dogs with SD
that persisted for a minimum of 1 treatment cycle. PFS was
defined as the interval from VDC-1101 treatment initiation to
PD. We were unable to assess PFS from the onset of lesions
because often this information was not available from RDVM
records and would have to have been approximated from owner
recollection. Dogs were censored from analysis if they were in
CR at the time of last treatment or lost to follow-up. The PFS
was calculated using the Kaplan-Meier product limit method,
which accounts for dogs that were in remission at the time of last
follow-up or lost to follow-up and are statistically referred to as
censored. All statistical analyses were performed by using a com-
mercial software package.b
Adverse events were graded according to the Veterinary
Cooperative Oncology Group Common Terminology Criteria
for Adverse Events v1.0,23 based on client history, physical
examination, CBC, biochemistry profile, and urinalysis. Assess-
ment of AEs was performed pretreatment and at all visits
thereafter. If dogs experienced ≥ grade 3 AEs, dose reduction
or delay was instituted unless the abnormality was judged not
attributable to VDC-1101. Because of difficulty in discriminat-
ing cutaneous toxicity from PD of CTCL, a biopsy was per-
formed if a dermatopathy was observed. Because of the
previous observation of pulmonary fibrosis as a late complica-
tion in a small percentage of VDC-1101 treated dogs,17 all dogs
underwent baseline thoracic radiography and repeat thoracic
radiography every other month for duration of the trial. When-
ever possible, postmortem examinations were performed at the
time of death.
Results
Treatment and Outcome
Twelve dogs with CTCL were enrolled prospectively
in a clinical trial of VDC-1101 with prednisone. Patient
and disease characteristics are presented in Table 2.
Ten dogs had epitheliotropic T-cell lymphoma, whereas
2 dogs were diagnosed with nonepitheliotropic lym-
phoma. Clinical presentation of dogs varied, and the
specific clinical presentation of each patient was not
consistently provided in the medical records for each
individual case. Investigators were asked to report
upon cutaneous target lesions (up to 5 per dog) and
these were the lesions that were followed up for
response assessment. Therefore, information regarding
total number of lesions or specific characterization of
lesions was not available. The 5 pretreated dogs
received a variety of cytotoxic chemotherapy protocols
(all received CCNU with or without additional proto-
cols), and all had PD at study enrollment. Four of
these 5 dogs had also received treatment with corticos-
teroids. An additional 4 dogs had previously received
corticosteroids. If dogs were receiving prednisone at the
time of trial entry, their dosage was adjusted to 1 mg/
kg q48h. Of the 11 dogs eligible for response assess-
ment, 1 experienced a CR (Fig 1) and 4 experienced
PR, for an overall response rate of 45% and biologic
response rate of 64% (including 2 dogs with SD). The
median PFS of all dogs was 37.5 days. The dog experi-
encing a CR had multifocal lesions that were erythema-
tous and scaling, and localized to the lateral thorax
bilaterally. Histologically, this dog was diagnosed with
nonepitheliotropic cutaneous lymphoma. The other
dog in the study with nonepitheliotropic lymphoma
experienced rapid progressive disease 9 days after treat-
ment. The 4 dogs that experienced PR had diverse clin-
ical presentations. All had diffuse skin lesions and 1
dog had concurrent mucocutaneous involvement. Two
of these dogs were na€ıve to treatment and 2 had
received previous treatment.
The response rate in previously treated dogs was
50% (2/4) and in chemotherapy-na€ıve dogs was 43%
(3/7). One dog died 2 days after treatment. On initial
presentation, this dog had severe regenerative anemia
(hematocrit, 20%) and an inflammatory leukogram.
Clinically, at the time of enrollment, the dog had a
poor appetite and was reported to be lethargic but
met the inclusion requirement based on performance
score. This dog did not meet the inclusion criteria
based on its hematocrit, but was approved for enroll-
ment by the study investigator because the dog had
exhausted all other therapeutic options. Postmortem
examination identified widespread lymphoma with
secondary severe bacterial pyoderma. In addition to
the skin, lymphoma was found in the lymph nodes,
heart, kidneys, and bone marrow. The acute cause of
death was suspected to be cardiac failure secondary
to lymphoma infiltration. Although this dog was not
evaluable for response assessment, it was included in
PFS outcome analysis.
Two dogs were censored in the PFS analysis: 1 dog
achieved CR that has persisted for >399 days without
relapse at the time of data analysis, and the second
dog had a dose-limiting dermatopathy followed by loss
to follow-up. The overall median PFS was 37.5 days
(2 to >399 days). The median PFS of na€ıve dogs was
43 days (9 to >399 days) compared to 21 days (2–
84 days) in pretreated dogs (P = .25; Fig 2). The dog
that achieved long-term CR had not previously
received chemotherapy or corticosteroids.
Safety and Adverse Events
Adverse events were transient and self-limiting in
most dogs and are described in Table 3. No grade 3 or
4 events were observed. However, 3 dogs (25%)
Table 2. Patient characteristics: Pretreated dogs
include dogs that received previous cytotoxic chemo-
therapy.
Median age, years (range) 9 (4–14)
Median weight, kg (range) 36 (10.1–45.7)
Sex
Male 4
Female 8
Breed
Golden retriever 4
Labrador retriever 2
Mix 1
Other (1 each) 5
Pretreatment
Yes 5
No 7
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developed dermatopathy. Biopsies were performed in 2
dogs and supported that the changes were consistent
with drug-induced toxicity as opposed to PD. More
specifically, histopathology in these 2 dogs disclosed
mixed dermatitis and hyperkeratosis, without evidence
of neoplasia. One dog was removed from the trial pre-
maturely after the lesions did not resolve after a 21-
day dose delay. This patient continued to have SD
throughout the dose delay and then was lost to follow-
up. Another dog that developed dermatopathic AE
received a 20% dose reduction and the dermatopathy
improved. This dog developed new target lesions
3 weeks later and was withdrawn. A biopsy was not
performed in this dog, but the reported lesions were
consistent with those reported previously with drug-
associated toxicity19 (ie, erythema and alopecia of the
pinnae) and clinically were distinct from the lymphoma
lesions.
Postmortem examinations were performed in 3
dogs. All 3 necropsies showed evidence of lymphoma
with no drug-associated pathologic findings noted.
There was no evidence of pulmonary fibrosis in
these 3 dogs. No dogs developed clinical or radio-
graphic evidence of pulmonary fibrosis while on
study.
Discussion
Despite the relatively high response rates observed
with classical treatment of canine CTCL, response
durations generally are not durable leading to the need
for additional therapies. VDC-1101, a novel prodrug
of the guanine nucleotide analog PMEG, has antitu-
mor activity and acceptable tolerability in dogs with
NHL.14,19–21 One of the observed toxicities was a der-
matopathy, implying delivery of drug to the skin.
Based on this possible therapeutic target, we investi-
gated the activity of VDC-1101 in dogs with naturally
occurring CTCL.
VDC-1101 showed activity against canine CTCL
with an ORR of 45% and median PFS in all patients
of 37.5 days. The activity observed in both untreated
and chemotherapy-refractory patients indicates poten-
tial utility for VDC-1101 in both induction and rescue
chemotherapy settings. A statistical difference in PFS
was not identified between na€ıve and refractory
Fig 1. Photographs of the complete responder before treatment, and 3 weeks, 6 months, and 11 months after treatment. Thoracic
radiographs continue to be normal.
Fig 2. Kaplan-Meier curve depicting progression-free survival of
na€ıve (n = 7) versus refractory dogs (n = 5). There was no signifi-
cant difference in outcome associated with pretreatment.
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patients. Some of the patients in the na€ıve category
had received corticosteroids previously, and it is
unknown how this could have affected response to
treatment. In addition, VDC-1101 resulted in SD in an
additional 2 dogs yielding a biologic response rate of
64%. In patients with advanced CTCL, the ability to
achieve SD is a benefit to patients because it helps pro-
long an acceptable quality of life.
Objective response assessment of CTCL lesions can
be challenging. The authors attempted to standardize
assessment as much as possible. In dogs with multiple
lesions, up to 5 target lesions were identified and these
lesions were followed, measured, and recorded at each
visit. Photographs also were obtained based on indi-
vidual clinician preference to help in response assess-
ment. In some cases of CTCL, lesions can progress in
severity but not in size. Therefore, the subjective
assessment of response by the primary clinician also
was provided. While this subjectivity may affect the
response rate, every attempt was made to standardize
response assessment.
Dogs were treated that had variable clinical presen-
tations, severity of lesions, duration of clinical signs,
and previous treatments. The authors acknowledge
that specific variants of CTCL are known to exist and
that these may carry different prognoses. Furthermore,
dogs presenting with advanced clinical presentations in
general have a poorer prognosis. The aim of this study
was to demonstrate responses with VDC-1101 in a
wide variety of CTCL cases. Based on the lack of sta-
tistical power with this initial investigation into the
activity of VDC-1101in CTCL, no conclusions regard-
ing responses in different clinical or histologic forms
could be made. Currently, there is no variation in
treatment recommendations for these clinical and his-
tologic variants and more information is needed to
assess how these specific clinical forms of disease
respond to differences in treatment.
A limitation of the study was the small number of
cases reported. One aim of this initial prospective
phase II clinical trial was to identify a >25%
response rate. It was determined that 12 dogs would
be adequate to assess this change and the authors
identified a 45% response rate. Although it would
be beneficial to evaluate a larger number of patients,
this initial information provides preliminary evi-
dence that VDC-1101 has efficacy in some dogs
with CTCL and is a potential treatment for this
disease. Additional studies would be necessary to
compare VDC-1101 to conventional chemotherapy
treatments.
Another potential limitation of the study was the
concurrent use of prednisone in conjunction with
VDC-1101. Prednisone was prescribed concurrently
at an anti-inflammatory dosage in effort to delay or
prevent a dose-limiting cutaneous or pulmonary tox-
icity. We acknowledge that corticosteroids can induce
short-term clinical improvement in dogs with lym-
phoid neoplasia. However, we feel that any relevant
antineoplastic effects are unlikely at the dosing sche-
dule used in this study. Many patients (n = 9) had
been exposed to high doses of corticosteroids before
enrollment in the study (alone or in combination
with other chemotherapy) with documented PD.
Therefore, it seems unlikely that any responses in
this study were secondary to the relatively low dos-
age of prednisone used. Furthermore, responses to
prednisone, if observed, would be expected to be
brief in duration. Corticosteroid use did make it dif-
ficult to attribute any possible antipruritic effects to
VDC-1101.
VDC-1101 was well tolerated. Acute AEs were mild
and manageable with no grade 3 or 4 toxicities
observed. These events were consistent with those
described in normal dogs and in dogs with NHL trea-
ted with GS-9219, with the exception that there were
no cases in this study that developed pulmonary fibro-
sis.14,19 The lack of pulmonary fibrosis observation
could be secondary to concurrent administration of
prednisone in this study, the small numbers of dogs
necropsied, or the relatively short overall survival
times observed with CTCL patients. The dog that
experienced CR continued to have normal thoracic
auscultation and unremarkable thoracic radiographs
>1 year after treatment.
Two dogs that progressed while on study (ie,
development of new lesions) were continued on
VDC-1101 based on compassionate use because the
owners reported improved quality of life while the
dogs were receiving the drug, as a result of stabiliza-
tion or improvement in originally identified lesions.
One of these dogs received an additional 3 treatment
cycles before decreases in quality of life were
observed, and the other dog received an additional
dose before treatment was changed to lomustine
based on the emergence of new lesions. It is there-
fore possible that VDC-1101 can improve quality of
Table 3. Summary of adverse events in 12 dogs with
CTCL receiving VDC-1101.
Adverse Event Grade n
Anorexia 1 3
2 1
Vomiting 1 1
2 1
Nausea 1 1
Diarrhea 1 1
Lethargy 1 2
Anemia 1 2
Neutropenia 1 1
Thrombocytopenia 1 1
Dermatopathy 1 1
2 2
Othera 1 6
2 1
aThis includes events of unknown etiology (proteinuria, low
albumin, hyperphosphatemia, elevated blood urea nitrogen, ele-
vated creatinine kinase, and hypokalemia). There were 4 events
related to elevated liver enzyme activities that were deemed sec-
ondary to prednisone administration and are not included in the
Table.
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life in patients even in the face of mild disease
progression.
In conclusion, VDC-1101 in combination with pred-
nisone exhibits activity against na€ıve and refractory
CTCL in dogs with an acceptable AE profile. The
observation of a long-term CR in 1 dog is encourag-
ing. Pulmonary fibrosis was not observed, but because
of the limited number of dogs and short survival times,
continued monitoring of thoracic radiographs is
recommended.
Footnotes
a VetDC, Fort Collins, CO
b Prism v6.0; GraphPad Software, LaJolla, CA
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